Form 4: Acrivon Therapeutics Chief Legal Officer Reports Stock Transaction
SEC Form 4 Filing
Mary Miller, Chief Legal Officer of Acrivon Therapeutics, reports a transaction involving the withholding of shares to cover tax obligations upon vesting of restricted stock units.
Summary
- On October 17, 2024, Mary Miller, the Chief Legal Officer of Acrivon Therapeutics, Inc., reported a transaction on Form 4.
- The transaction involved the withholding of 558 shares of common stock at a price of $7.87 per share.
- These shares were withheld by Acrivon Therapeutics to satisfy the mandatory tax withholding requirement upon the vesting of restricted stock units.
- Following the reported transaction, Miller beneficially owns 38,125 shares of Acrivon Therapeutics, Inc.
Sentiment
Score: 7
Explanation: The document is a routine regulatory filing detailing a standard tax withholding transaction, which is neither particularly positive nor negative.
Industry Context
Form 4 filings are standard practice for reporting transactions by company insiders, providing transparency to investors.
Key Dates
| Date | Description |
|---|---|
| 10/17/2024 | Date of the stock transaction (withholding of shares). |
| 10/21/2024 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.